IL6R and rheumatoid arthritis: Although several earlier meta-analyses examined the safety and effectiveness of JAK or IL-6R inhibitors in the treatment of RA [9,10,30,31,35], we conducted our meta-analysis using more rigorous criteria and incorporating only high-quality evidence as provided by double-blind placebo-controlled RCTs.